Zoetis Inc. $ZTS Stock Position Lifted by Allstate Corp

Key Points

• Allstate Corp more than doubled its Zoetis stake in the fourth quarter, increasing holdings by 106.1% to 32,227 shares valued at about $4.06 million.
• Several other institutional investors also boosted positions in Zoetis, and institutional ownership stands at 92.8%, showing strong interest from large funds.
• Zoetis recently reported Q1 earnings of $1.53 per share, missing estimates, while revenue came in at $2.26 billion; the company also announced a quarterly dividend of $0.53 per share yielding 2.7%.

Allstate Corp grew its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 106.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,227 shares of the company's stock after buying an additional 16,592 shares during the period. Allstate Corp's holdings in Zoetis were worth $4,055,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Diamond Hill Capital Management Inc. acquired a new position in shares of Zoetis during the 3rd quarter valued at $394,010,000. Nordea Investment Management AB increased its position in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. Montrusco Bolton Investments Inc. increased its position in shares of Zoetis by 256.7% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company's stock valued at $266,888,000 after purchasing an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Zoetis by 83.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock valued at $394,746,000 after purchasing an additional 1,227,085 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares of the company's stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio acquired 6,650 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last three months. Corporate insiders own 0.22% of the company's stock.

Zoetis Price Performance

ZTS opened at $79.48 on Thursday. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $172.23. The stock has a fifty day moving average price of $105.95 and a 200 day moving average price of $117.60. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market cap of $33.32 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 1.31 and a beta of 0.87.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the business earned $1.48 earnings per share. Zoetis's quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis's dividend payout ratio (DPR) is 35.16%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZTS. JPMorgan Chase & Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Wall Street Zen cut Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Finally, Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a "buy" rating for the company in a research report on Monday, May 18th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Zoetis has a consensus rating of "Hold" and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.